Severe atopic dermatitis treated with everolimus

Journal of Dermatological Treatment

Volumn 20, Issue 6, 2009, Pages 365-367

  Van Velsen, Sara Gertrudes Anna ^a   Haeck, Inge Marjet ^a   Bruijnzeel Koomen, Catharina Ansfrieda Francisca Maria ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atopic dermatitis; Everolimus

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; PREDNISONE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; LOW DRUG DOSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TREATMENT FAILURE;

EID: 72449156139     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903085294     Document Type: Article

References (13)

1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483-1494
2. Santamaria-Babi LF. Skin-homingT cells in cutaneous allergic inflammation. Chem Immunol Allergy. 2006;91:87-97.
3. Behnam SM, Behnam SE, Koo JY. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol. 2005;4:189-194
4. Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338:137-140
5. Hijnen DJ, ten Berge O, Timmer-de Mik L, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol. 2007;21:85-89
6. Schuurman HJ, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation. 1997;64: 32-35
7. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83-95.
8. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial. Br J Dermatol. 2001;145:438-5.
9. Frigerio E, Colombo MD, Franchi C, Altomare A, Garutti C, Altomare GF, et al. Severe psoriasis treated with a new macrolide: Everolimus. Br J Dermatol. 2007;156:372-4.
10. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A, et al. Clinical validation and guidelines for the SCORAD index: Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195:10-19
11. Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis. 2005;64: (suppl 2)ii30-6.
12. Lebwohl M. Psoriasis. Lancet. 2003;361:1197-1204
13. Kahan BD, Wong RL, Carter C, Katz SH, Von Fellenberg J, Van Buren CT, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients.Transplantation. 1999;68:1100-1106